<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788099</url>
  </required_header>
  <id_info>
    <org_study_id>APL-A-010-08</org_study_id>
    <nct_id>NCT00788099</nct_id>
  </id_info>
  <brief_title>Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas</brief_title>
  <official_title>Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in&#xD;
      Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas&#xD;
      to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in&#xD;
      combination with sorafenib or gemcitabine in patients with advanced solid tumors or&#xD;
      lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in&#xD;
      Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas&#xD;
      to determine the maximum tolerated dose (MTD) and the recommended dose (RD), the&#xD;
      pharmacokinetics (PK) of these combinations, drug-drug PK interactions, preliminary&#xD;
      information on the clinical antitumor activity of these combinations in solid tumors,perform&#xD;
      a preliminary pharmacogenomic (PGx) study of potential biomarkers of sensitivity/resistance&#xD;
      to these drugs combinations and of prognostic markers of the treatment outcome in tumor&#xD;
      tissue sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.</measure>
    <time_frame>Along the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize safety profile and feasibility, pharmacokinetics, drug-drug interactions. To obtain information on antitumor activity.</measure>
    <time_frame>Along the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Lymphomas</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plitidepsin and Sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and Plitidepsin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin and Sorafenib</intervention_name>
    <description>Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and Plitidepsin</intervention_name>
    <description>Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status (PS) of ≤ 1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Patients with histologically/cytologically confirmed diagnosis of advanced solid&#xD;
             tumors or lymphomas (excluding B-cell derived lineage and/or primary cutaneous and/or&#xD;
             leukemic disease) refractory to standard therapy and with reasonable chance to benefit&#xD;
             from any of these combinations according to the investigator's opinion.&#xD;
&#xD;
          -  Patients entered at the expansion cohort of the RD must have: a) measurable disease&#xD;
             according to RECIST, or to International Working Group Criteria (IWC) for lymphoma&#xD;
             patients or b) Evaluable disease by serum markers in the case of prostate and ovarian&#xD;
             cancer (according to Prostate-Specific Antigen Working Group Recommendations (PSAWGR)&#xD;
             and Gynecologic Cancer Intergroup (GCIG) specific criteria, respectively&#xD;
&#xD;
          -  At least 4 weeks since last chemotherapy (6 weeks since nitrosoureas and mitomycin C),&#xD;
             immunotherapy or any other pharmacological treatment and radiotherapy. In the case of&#xD;
             hormone-sensitive cancer progressing while on hormone therapy (i.e., breast, prostate&#xD;
             cancer), hormone therapy must be either stopped 4 weeks before or continued during the&#xD;
             trial&#xD;
&#xD;
          -  Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ 7 days before&#xD;
             inclusion in the study): a) Platelet count ≥100 x109/L (≥ 75 x 109/L for lymphoma&#xD;
             patients), hemoglobin ≥9.0 g/dL (≥ 8.0 g/dL for lymphoma patients) and absolute&#xD;
             neutrophil count (ANC) ≥1.5 x109/L (≥1.0 x109/L for lymphoma patients). b) Aspartate&#xD;
             Aminotransferase (AST) and Alanine Aminotransferase (ALT): ≤ 3.0 x the upper limit of&#xD;
             normal (ULN), independently of the presence of liver metastases. c) AP ≤2.5 x ULN (≤5&#xD;
             x ULN in case of extensive bone metastases). d) Total bilirubin ≤1.5 x ULN (unless due&#xD;
             to indirect hyperbilirubinemia for the gemcitabine combination arm only). e)&#xD;
             Calculated CrCl: ≥ 40 mL/minute (by means of Crockroft and Gault´s formula). f) CPK ≤&#xD;
             2.5 x ULN. g) Albumin ≥2.5 g/dL. h) Troponin I ≤ULN&#xD;
&#xD;
          -  Recovery to grade ≤1 from any AE derived from previous treatment (excluding alopecia&#xD;
             of any grade and peripheral neuropathy ≤ grade 2)&#xD;
&#xD;
          -  LVEF by ECHO or MUGA above the lower normal limit.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test before study&#xD;
             entry. Both women and men must agree to use a medically acceptable method of&#xD;
             contraception throughout the treatment period and for 3 months after discontinuation&#xD;
             of treatment. Acceptable methods of contraception include complete abstinence,&#xD;
             intrauterine device (IUD), oral contraceptive, subdermal implant and double barrier&#xD;
&#xD;
          -  Voluntarily signed and dated written informed consent prior to any specific study&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with any of the study drugs (in the expansion cohort at the RD).&#xD;
&#xD;
          -  Concomitant diseases/conditions:&#xD;
&#xD;
               -  History or presence of unstable angina, myocardial infarction, valvular heart&#xD;
                  disease or congestive heart failure.&#xD;
&#xD;
               -  Previous mediastinal radiotherapy.&#xD;
&#xD;
               -  Previous treatment with doxorubicin at cumulative doses in excess of 450 mg/m2&#xD;
&#xD;
               -  Symptomatic arrhythmia or any arrhythmia requiring ongoing treatment, and/or&#xD;
                  prolonged QT-QTc &gt; to grade 1.&#xD;
&#xD;
               -  Active uncontrolled infection.&#xD;
&#xD;
               -  Myopathy or any clinical situation that causes significant and persistent&#xD;
                  elevation of CPK (&gt;2.5 x ULN in two different determinations performed with one&#xD;
                  week apart).&#xD;
&#xD;
               -  Limitation of the patient's ability to comply with the treatment or follow-up&#xD;
                  protocol.&#xD;
&#xD;
               -  Any other major illness that, in the Investigator's judgment, will substantially&#xD;
                  increase the risk associated with the patient's participation in this study.&#xD;
&#xD;
               -  Peripheral neuropathy &gt;grade 2&#xD;
&#xD;
          -  Symptomatic, progressive or requiring-corticosteroids documented brain metastases or&#xD;
             leptomeningeal disease. Controlled and stable brain metastases without steroids are&#xD;
             allowed&#xD;
&#xD;
          -  Men or women of childbearing potential who are not using an effective method of&#xD;
             contraception as previously described; women who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients who have had radiation therapy in greater than 35% of the bone marrow&#xD;
&#xD;
          -  History of previous bone marrow and/or stem cell transplantation. (Not for patients&#xD;
             treated at RD in the expansion cohort)&#xD;
&#xD;
          -  High transfusional requirements (&gt; 2 packages of red blood cells and/or 1 platelets&#xD;
             transfusion) in the 30 days prior to inclusion in the study&#xD;
&#xD;
          -  Participation in another clinical trial or concomitant treatment with any&#xD;
             investigational product in the 30-day period prior to inclusion in the study.&#xD;
&#xD;
          -  For sorafenib treatment only: a) Hypersensitivity to sorafenib or any component of the&#xD;
             formulation. b) Need of chronic exposure to antacids, H-2 antagonists or proton-pump&#xD;
             inhibitors. c) Current need for anticoagulation treatment (including low dose warfarin&#xD;
             and LMWH treatment at full anticoagulant doses).&#xD;
&#xD;
          -  Abnormal thyroid function [as per normal serum thyroid stimulating hormone (TSH)&#xD;
             within 14 days of first dose of study treatment).&#xD;
&#xD;
          -  Uncontrolled arterial hypertension (≥160/100) despite optimal medical therapy.&#xD;
&#xD;
          -  Child-Pugh grade C hepatic cirrhosis of any cause&#xD;
&#xD;
          -  For gemcitabine treatment only:&#xD;
&#xD;
               -  Hypersensitivity to gemcitabine or any component of the formulation.&#xD;
&#xD;
               -  Impending need for palliative radiotherapy to ameliorate painful metastases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark N. Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Charles Soria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cancer Institute of New Jersey (CINJ)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pharmamar USA</name_title>
    <organization>Pharmamar USA</organization>
  </responsible_party>
  <keyword>Aplidin</keyword>
  <keyword>Plitidepsin</keyword>
  <keyword>Tumors</keyword>
  <keyword>Lymphomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

